Heterogeneous nuclear ribonucleoproteins (hnRNPs) and human transformer-2-beta1 (hTra2-beta1)-regulated estrogen receptor-alpha improves prognosis of endometrial cancer.
Eur J Gynaecol Oncol
; 35(6): 701-7, 2014.
Article
en En
| MEDLINE
| ID: mdl-25556278
ABSTRACT
PURPOSE OF INVESTIGATION Heterogeneous nuclear ribonucleoprotein (hnRNP) family possesses decreasing effect towards endometrial cancer (EC) and human transformer-2-betal (hTra2-betal) performs an intimate relationship with EC, either. Recent study shows that hnRNPs and hTra2-betal regulate the genetic expression, which is concerned with estrogen receptor (ER). MATERIALS AND METHODS:
The present study was designed to investigate the link between ER and hnRNPs or hTra2-betal in the prognosis of EC patients by Real-time PCR and immunohistochemisty (IHC).RESULTS:
Results showed that ER protein expression presented a significant change in the recurrence and outcome of EC patients, and the nucleus hTra2-betal protein expression was also increased in the recurrent patients, indicating that the three might be important in ER expression in the prognosis therapy of EC patients.CONCLUSION:
The present findings provide an insight of pharmaceutical targeting therapy and prognosis of EC.
Buscar en Google
Colección:
01-internacional
Banco de datos:
MEDLINE
Asunto principal:
Proteínas de Unión al ARN
/
Neoplasias Endometriales
/
Ribonucleoproteínas Nucleares Heterogéneas
/
Receptor alfa de Estrógeno
/
Proteínas del Tejido Nervioso
Tipo de estudio:
Prognostic_studies
Límite:
Female
/
Humans
Idioma:
En
Revista:
Eur J Gynaecol Oncol
Año:
2014
Tipo del documento:
Article
País de afiliación:
China